NSCLC Clinical Trial Tracker — Stay Ahead of the Lung Cancer Pipeline

Why NSCLC trial monitoring matters

Non-small cell lung cancer is one of the most active therapeutic areas in oncology. With over 800 active NSCLC trials on ClinicalTrials.gov at any given time, manually tracking new programs, competitor updates, and recruiting status changes is a significant time burden for pharma BD teams, biotech analysts, and clinical research organizations.

Key signals that NSCLC professionals track:

• New Phase 2/3 programs targeting KRAS G12C, EGFR exon 20, ALK fusions, and emerging targets
• Status changes: trials that begin recruiting or transition from Phase 2 to Phase 3
• Competitor pipeline moves — new sponsorships, trial extensions, or terminations
• NIH-funded investigator-initiated studies that preview emerging mechanisms
• Combination regimens involving approved checkpoint inhibitors

What TrialPulse monitors for NSCLC

TrialPulse pulls directly from the ClinicalTrials.gov API every day. For an NSCLC watch profile, you can configure:

• Condition keywords: "non-small cell lung cancer", "NSCLC", "lung adenocarcinoma", "squamous cell lung", "KRAS G12C", "EGFR mutation"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors (including NIH and academic)
• Status filter: Recruiting only, all active studies, or any status including completed/terminated

How it compares to ClinicalTrials.gov RSS alerts

ClinicalTrials.gov does have a basic RSS/email notification system, but it has significant limitations for professional use:

• No phase filtering — you get every Phase 1 first-in-human study alongside major Phase 3 trials
• No sponsor type filtering — academic, NIH, and industry trials are mixed together
• No clear labeling of "new" vs. "updated" trials — everything looks the same
• No support for multiple simultaneous search profiles
• Difficult to set up and manage for non-technical users

TrialPulse delivers filtered, labeled, and organized alerts — the intelligence layer on top of the raw data.

Who uses NSCLC trial monitoring

Pharma business development teams

BD teams at mid-size and large pharmaceutical companies track competitor pipeline activity to inform partnership, licensing, and acquisition decisions. A new Phase 2 KRAS G12C program from an emerging biotech is valuable intelligence — knowing about it the day it's posted matters.

Biotech analysts and investors

Investors covering oncology track clinical trial starts and status changes as leading indicators of pipeline value. A Phase 3 initiation or a positive status update can precede a catalyst by months.

Clinical research organizations (CROs)

CROs track new trial registrations to identify prospective clients whose trials are entering the active phase and will need site management, data management, or patient recruitment services.

Patient advocacy organizations

Lung cancer patient groups monitor new recruiting trials to help patients find clinical trial opportunities matching their mutation profile and treatment history.

Frequently asked questions

How current is the NSCLC trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov itself is updated continuously as sponsors submit changes.

Can I track multiple NSCLC sub-targets simultaneously?

Yes. On the Pro plan ($129/month), you can create up to 5 search profiles. You might have one profile for KRAS G12C programs, another for EGFR exon 20, and another for broad Phase 3 recruiting trials — each delivered as a separate daily digest.

Does TrialPulse cover international trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — international NSCLC trials registered on ClinicalTrials.gov are included. This covers most major industry-sponsored programs worldwide.